- AstraZeneca's Imfinzi receives EU approval for NSCLC treatment with chemotherapy.
- Analysts predict a potential 34.49% upside for AstraZeneca stock.
- Current brokerage ratings indicate an "Outperform" status for AZN.
The European Commission has given the green light for AstraZeneca's (AZN, Financial) Imfinzi to be used in combination with chemotherapy for the treatment of resectable non-small cell lung cancer (NSCLC) in adults at a high risk of recurrence. This significant decision stems from a pivotal Phase III trial, demonstrating noteworthy reductions in recurrence, progression, and mortality rates.
Wall Street Analysts Forecast
According to the analyses of 10 esteemed analysts, AstraZeneca PLC (AZN, Financial) is poised for an average target price of $87.28 over the next year, with projections ranging from a high of $97.00 to a low of $67.00. This average target indicates a promising upside of 34.49% from its current trading price of $64.90. For further insights and detailed estimates, explore the AstraZeneca PLC (AZN) Forecast page.
Market sentiment from 12 brokerage firms culminates in an average recommendation of 1.8 for AstraZeneca PLC (AZN, Financial), suggesting an "Outperform" status. This rating scale spans from 1 to 5, where 1 signifies a Strong Buy and 5 suggests a Sell recommendation.
Delving into GuruFocus projections, the anticipated GF Value for AstraZeneca PLC (AZN, Financial) in the coming year hovers at $86.83, signaling a potential upside of 33.79% from its current $64.90 price point. This GF Value reflects GuruFocus's assessment of the stock's fair trading value, grounded on historical trading multiples, past growth metrics, and forward-looking business performance estimates. To access more comprehensive data, visit the AstraZeneca PLC (AZN) Summary page.
